The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...
The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...
SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research...
The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...
The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.
The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...